title: Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
abstract: OBJECTIVE
  Only a small number of comprehensively characterized immortalized ovarian cancer cell lines are available for laboratory studies on ovarian cancer. We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882.
  
  
  METHODS
  We characterized CSOC 882 by karyotyping, growth modeling, immunohistochemical staining, immunoblotting, drug sensitivity testing, and xenografting in nude mice.
  
  
  RESULTS
  CSOC 882 possessed an abnormal tetraploid karyotype including loss of one copy of chromosomes 2, 17, 19, and 21, and deletion of 8p21. Growth of CSOC 882 was best modeled using the logistic growth equation revealing an average doubling time of 31 h. CSOC 882 cells expressed vimentin, cytokeratin, p53, BRCA1, EGF receptor, HER2, androgen receptor, estrogen receptor alpha, and progesterone receptor, while no evidence of estrogen receptor beta or factor VIII was observed. Some but not all CSOC 882 cells were positive for CA125 reflecting the primary tumor, which had patchy CA125 staining. Drug sensitivity assays demonstrated that CSOC 882 was more sensitive to cisplatin and carboplatin than SKOV3 and HCC1937 while CSOC 882 and SKOV3 were both sensitive to paclitaxel unlike HCC1937. CSOC 882 xenografts retained the original characteristics of vimentin, cytokeratin, and factor VIII labeling.
  
  
  CONCLUSIONS
  CSOC 882 is an immortalized cell line that has survived more than 130 passages in culture and retained molecular features of the primary tumor from which it was derived. Compared to the most common ovarian carcinoma cell lines, CSOC 882 is a unique resource for genetic and cellular research on ovarian cancer.
authors.affiliation: Women's Cancer Research Institute at Samuel Oschin Comprehensive Cancer Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. scolesd@cshs.org
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Scoles
authors.forename: James
authors.initials: J
authors.lastname: Pavelka
authors.forename: Ilana
authors.initials: I
authors.lastname: Cass
authors.forename: Hang
authors.initials: H
authors.lastname: Tran
authors.forename: Rae L
authors.initials: RL
authors.lastname: Baldwin
authors.forename: Klara
authors.initials: K
authors.lastname: Armstrong
authors.forename: Beth Y
authors.initials: BY
authors.lastname: Karlan
mesh_terms: D000818:Animals; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D003582:Cytogenetics; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D051057:Proto-Oncogene Proteins c-akt / Q000096:biosynthesis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D014183:Transplantation, Heterologous
chemical_list: D066246:ErbB Receptors; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases